In recent years, immunotherapy such as programmed cell death 1 (PD-1) and programmed cell death ligand (PD-L1) inhibitors has shown clinical success in treating a range of solid tumors, particularly advanced cancer patients (10). This evidence concerns the gene CD274 and cancer.